Melbourne, May 15, 2026, 05:02 AEST
CSL Limited shares ended lower on Thursday, extending a harsh week for the Australian biotechnology group after a profit downgrade and planned writedowns shook confidence in one of the ASX’s former blue-chip favourites. The stock closed at A$97.26, down 1.55%, according to delayed market data published after the close.
The move matters now because the CSL share price is still pinned near levels last seen in early 2017, after Monday’s 90-day review under interim chief executive Gordon Naylor triggered a fresh selloff. Reuters reported that the stock fell as much as 17.8% on Monday to A$98.590, its lowest since Jan. 19, 2017.
In that review, CSL cut its FY26 revenue outlook to around US$15.2 billion and NPATA to around US$3.1 billion, both on a constant-currency basis, which strips out exchange-rate moves. NPATA is CSL’s adjusted profit measure before amortisation of acquired intellectual property and significant one-off items such as restructuring and impairments.
The company also expects about US$5 billion in additional non-cash, pre-tax impairments across FY26 and FY27. An impairment is an accounting charge that lowers the value of assets on the books. CSL said the charges include CSL Vifor intangible assets, parts of the product portfolio and under-used property, plant and equipment.
Naylor told investors CSL’s growth plans are working, but the “financial benefits will take longer.” On a conference call, he also cited late-stage R&D misses and market-share losses, while stressing there was “no fundamental shift” in strategy. Chief financial officer Ken Lim pointed to “excess Ig inventory in the channel” as a drag on reported U.S. immunoglobulin sales. Fierce Pharma
The market is not giving CSL much benefit of the doubt. Mark Gardner, founder and CEO of MPC Markets, told Reuters the latest guidance cut was the second trim in roughly six months and said “that pattern matters.” Back-to-back downgrades, he added, raise “legitimate questions” about the company’s visibility into its own business. Sahm
The near-term pressure points are specific. CSL expects roughly US$300 million of revenue impact from U.S. immunoglobulin inventory normalisation, about US$200 million from lower albumin market value in China, and about US$150 million from the Middle East conflict, revised Hemgenix growth and competition in iron products. Immunoglobulin, or Ig, is an antibody-rich plasma product used to treat immune and neurological disorders.
Competition is part of the backdrop. The global immunoglobulin market is concentrated, with CSL facing large rivals including Takeda Pharmaceutical, Grifols and Octapharma. That does not make CSL’s problem purely external, but it raises the cost of poor execution when inventory, pricing and field-force decisions move against the company.
Vifor remains the scar investors keep returning to. CSL agreed in 2021 to buy the Swiss iron-deficiency and nephrology specialist for an aggregate equity value of US$11.7 billion, saying at the time it would diversify and expand the group’s growth base. The new writedown shows how much of that deal is now being reassessed.
There is also a leadership reset. CSL said the search for a permanent CEO is progressing, while chief commercial officer Andy Schmeltz will retire for personal reasons. Diego Sacristan is due to take over as chief commercial officer for CSL Behring and CSL Vifor on July 1.
But the reset is not finished. The impairments remain subject to further analysis, business developments, external audit and board approval, and any further weakness in U.S. channel inventory, China albumin pricing or iron competition could leave less room for the recovery narrative by the time full-year numbers land.
CSL is still telling investors there is something to salvage. It expects second-half revenue growth at CSL Behring and said CSL Seqirus, its vaccines business, should perform moderately better than previously expected in FY26. For now, the market wants proof, not another long-range promise.
